Spectrum's Rolontis Meets Primary Endpoint in Ph III Study for Neutropenia

Spectrum's Rolontis Meets Primary Endpoint in Ph III Study for Neutropenia

Source: 
CP Wire
snippet: 

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) announced on 6/29/2018 detailed data from the ADVANCE Phase 3 study which showed that Rolontis had an absolute risk reduction of severe neutropenia of 8.5 percent (95% CI: 0.2%, 16.2%) versus pegfilgrastim in Cycle 1.